nice88 com ph
The Atlanta Hawks (14-12) aim to continue a four-game road win streak when they visit the Milwaukee Bucks (13-11) on December 14, 2024. Watch the NBA, other live sports and more on Max. Use our link to sign up today. Catch NBA action all season long on Fubo. Get tickets for this game at StubHub . Sign up for NBA League Pass to get access to games, live and on-demand, and more for the entire season and offseason. Looking for officially licensed NBA gear? Fanatics has jerseys, hats, apparel, memorabilia, trading cards, collectibles and more. Catch NBA action all season long on Max. Watch ESPN originals, The Last Dance and more NBA content on ESPN+. Use our link to sign up for ESPN+ or the Disney bundle.
Did you know with an ad-lite subscription to Burnley Express, you get 70% fewer ads while viewing the news that matters to you. The Clarets extended their unbeaten run to 11 games by claiming a hard-earned point at the Riverside in their final game of 2024, just three days on from their big win against Sheffield United on Boxing Day. Parker, whose side are back in action again on New Year’s Day against Stoke City, had nothing but praise for his players, despite rueing a big Josh Brownhill miss that would have made it four wins on the spin. Advertisement Advertisement “I’m probably a little bit disappointed [not to get all three points],” he admitted. “I thought the game ebbed and flowed. But we have a glorious chance, in fact we have a couple to be fair, but we have a big chance with Browny and I don’t think you’d want a better man to put that in - he’s proven that over the course of the season - but he’s not managed to do that tonight. “I could forgive any of them for missing, but certainly Browny. “Overall it’s a good point. We’ve had some tough fixtures and I knew this would be a big test for us. Not just in terms of the opposition we were facing, but just in terms of where we were after a tough schedule. The fixtures have probably not been the best of friends since they came out at the start of the season - Sheffield United away on Boxing Day was a tough game and tonight as well. “But overall I’m really pleased with the team.” Advertisement Advertisement While Parker is pleased with the point, that’s not to say he was happy to settle for a draw having thrown on two strikers late on in search of a winner. It didn’t transpire, with Boro ending the game the stronger, but Parker felt he had to freshen things up having named an unchanged side for the third game running. “It was tempting to make changes, of course, but they’re the decisions as a manager you’re constantly having to face,” he added. “It wasn’t an easy decision but I think it was proven right. I did consider freshening things up to maybe give us a spark because we’ve just had a tough game at Sheffield United, but the players were superb. “We wanted to come here and get three points and I think the subs we made indicated that. We wanted to try and win the game. “We didn’t manage to do that but that was the idea.”Trastuzumab rezetecan is under clinical development by and currently in Phase I for Head And Neck Cancer. According to GlobalData, Phase I drugs for Head And Neck Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Trastuzumab rezetecan overview Trastuzumab rezetecan (SHRA-1811) is under development for the treatment of HER2 expressing or mutated advanced malignant solid tumor, human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), HER2-negative Advanced Breast Cancer, metastatic breast cancer, metastatic biliary cancer (BTC), advanced non-small cell lung cancer, metastatic colorectal cancer, gastric cancer, cervical cancer, recurrent ovarian cancer and endometrial cancer and adenocarcinoma of the gastroesophageal junction. It comprises of the anti-HER2 antibody trastuzumab, a cleavable linker, and the topoisomerase I inhibitor payload SHR169265. It is administered by intravenous and parenteral route. The drug candidate is an antibody drug conjugate which acts by targeting cells expressing tyrosine kinase type cell surface receptor HER2. Jiangsu Hengrui Medicine overview (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China. For a complete picture of Trastuzumab rezetecan’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .49ers QB Brock Purdy remains severely limited by injury to his throwing shoulder
GREEN BAY, Wis. (AP) — After losing to San Francisco in the playoffs three of the last five seasons, the Green Bay Packers wouldn’t mind seeing the 49ers get left out of the postseason entirely. The Packers (7-3) could damage San Francisco’s playoff hopes Sunday by beating the 49ers at Lambeau Field. San Francisco (5-5) dropped to .500 after losing at home to the Seattle Seahawks, though the 49ers remain just a game behind the Arizona Cardinals in the NFC West. “I think we’re motivated to keep winning more than anything,” Packers center Josh Myers said. “Obviously, they have knocked us out quite a bit. There’s that extra motivation behind it, but at this point, we’re just trying to churn out wins.” Green Bay is third in the NFC North and two games behind the Detroit Lions, but the Packers appear on track to at least earn a wild-card playoff berth. History suggests their path to a potential Super Bowl would get much clearer if the 49ers aren’t standing in their way. The 49ers trailed 21-14 in the fourth quarter before rallying to beat the Packers 24-21 in the divisional playoffs last year on Christian McCaffrey’s 6-yard touchdown run with 1:07 left. Now it’s the 49ers who are struggling to protect late leads, as they’ve blown fourth-quarter advantages in three games against divisional opponents. “You could look at, ‘Hey, we’re three possessions away from being 8-2,’ but you can’t really live like that,” 49ers tight end George Kittle said. “Those are the mistakes that we’ve made to be 5-5. It’s not exactly where we want to be. It is frustrating. The nice thing is we have seven games left to go out there and play Niners football and take advantage of those opportunities.” Green Bay’s recent history of playoff frustration against the 49ers also includes a 13-10 loss at Lambeau Field in the 2021 divisional playoffs and a 37-20 road defeat in the 2019 NFC championship game. Even the Packers who weren’t around for last season’s playoff loss realize what this game means. “I think one of the first meetings that I was in here, we had a conversation about the Niners beating us,” said Green Bay safety Xavier McKinney, who joined the Packers this season. “So I understand how important it is, and we all do.” Both teams must figure out how to convert red-zone opportunities into touchdowns. The 49ers are scoring touchdowns on just 48.8% of their drives inside an opponent’s 20-yard line to rank 27th in the NFL. The Packers are slightly worse in that regard, scoring touchdowns on 48.7% of their red-zone possessions to rank 28th. In their 20-19 victory at Chicago on Sunday, Green Bay drove to the Bears 5 without scoring on two separate series. Kittle expects to play Sunday after missing the Seahawks game with a hamstring injury, but four-time Pro Bowl edge rusher Nick Bosa’s status is uncertain after he hurt his left hip and oblique in that game. Seattle scored both of its TDs after Bosa left in the third quarter with an injury and averaged 2.7 additional yards per play after he got hurt. Packers cornerback Jaire Alexander didn’t play in the second half of the Bears game due to a knee injury that also prevented him from playing in a Nov. 3 loss to Detroit. Green Bay’s defense feasted on turnovers the first part of the season, but hasn’t been as effective in getting those takeaways lately. The Packers have 19 takeaways – already exceeding their 2023 total – but haven’t forced any turnovers in their last two games. 49ers coach Kyle Shanahan hasn’t eased McCaffrey back into the lineup in his return after missing the first eight games with Achilles tendinitis. McCaffrey has played 91% of the 49ers’ offensive snaps the past two weeks. Jordan Mason, who rushed for 685 yards during McCaffrey’s absence, has just five snaps on offense the last two games. Shanahan said he’d like to get Mason more opportunities, but it’s hard to take McCaffrey off the field. Green Bay nearly lost to the Bears because of its third-down struggles on both sides of the ball. The Packers were 1 of 5 on third-down opportunities, while the Bears went 9 of 16. The Packers’ defense could have a tough time correcting that problem against San Francisco, which has converted 45.4% of its third-down situations to rank fourth in the league. AP Pro Football Writer Josh Dubow contributed to this report. AP NFL: https://apnews.com/hub/NFLJimmy Carter, A Transformative Diplomat Despite Iran
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GCC-4001 overview GCC-4001 (AB-101) is under development for the treatment of rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis, B-cell non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, Waldenstrom Macroglobulinemia, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), R/R classical Hodgkin lymphoma, lupus nephritis (LN) and autoimmune disorders. The therapeutic candidate is an allogeneic, non-engineered, cord blood-derived natural killer (NK) cell therapy. It is administered through intravenous route and is being developed based on AlloNK platform. Artiva Biotherapeutics overview Artiva Biotherapeutics is a biotechnology company developing allogeneic natural killer (NK) cell therapies to treat hematologic cancers or solid tumors. It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric antigen receptor-modified natural killer) cell therapy targeting HER2 positive solid tumors; and AB-202 against CD19 positive B-cell malignancies. Artiva Biotherapeutics utilizes its proprietary CAR (chimeric antigen receptor) platform to improve NK cells’ therapeutic activity and tumor-targeting capability. Artiva Biotherapeutics is headquartered in San Diego, California, the US. For a complete picture of GCC-4001’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .
As U.S. goalkeeper Alyssa Naeher looked ahead to the next Women's World Cup in 2027, she calculated what that would look like at her age. Read this article for free: Already have an account? To continue reading, please subscribe: * As U.S. goalkeeper Alyssa Naeher looked ahead to the next Women's World Cup in 2027, she calculated what that would look like at her age. Read unlimited articles for free today: Already have an account? As U.S. goalkeeper Alyssa Naeher looked ahead to the next Women’s World Cup in 2027, she calculated what that would look like at her age. Now 36, she already has a World Cup title and won an Olympic gold medal this year in France. She considered the mental, physical and emotional toll of a new cycle and decided it was time to step away. “Honestly, I think I’ve been somebody that has given everything I’ve had to this team. I don’t do anything halfway. It’s kind of, if you can give 100% to it, then keep going,” she said. “With that in mind, I kind of just felt like this was the right time coming off of the Olympics, having the year that we had, entering into a new cycle, a new stage for this team.” Naeher is the latest veteran to announce she’s stepping down from the national team as the next generation takes over under coach Emma Hayes. Among those who have wrapped up their soccer careers in the past couple of years include World Cup winners Megan Rapinoe, Alex Morgan, Kelley O’Hara and Ali Krieger. Naeher will be with the team for two more matches in the coming week. The Americans play England at Wembley Stadium on Saturday and then the Netherlands in The Hague on Tuesday. Naeher said she’s excited about the next generation of goalkeepers. In addition to Naeher, Mandy Haught of the Utah Royals and Phallon Tullis-Joyce of Manchester United are on the roster for the upcoming matches. Other goalkeepers who have been on recent rosters include Casey Murphy and Jane Campbell. “I think the beauty of goalkeeping is that it’s not really a one-size-fits-all kind of position,” she said. “The more that you can understand — that’s going to be the challenge any young goalkeeper coming up, is really taking the time to understand what your strengths are and make them really, really elite and separate yourself.” Naeher spoke on Wednesday from London after announcing her retirement on social media Monday. Naeher made her senior debut with the national team in 2014 and was a backup to Hope Solo at the 2015 World Cup, which the United States won. She became the team’s regular starter following the 2016 Rio de Janeiro Olympics and was on the squad that repeated as World Cup winners in 2019. Naeher won a bronze medal at the Tokyo Olympics in 2021 before the U.S. earned gold this year in Paris. She made a key one-handed save in stoppage time to preserve the Americans’ 1-0 victory over Brazil in the Olympic final. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. For her career, Naeher has appeared 113 games with 110 starts, 88 wins and 68 shutouts. She had four shutouts over the course of the Olympic tournament in France. While she’s leaving the national team, she’ll play one more year for her club team, the Chicago Red Stars in the National Women’s Soccer League. “I hope that I can be remembered as a good teammate, as a competitor, as somebody that was looked on as someone that could be relied upon on the field and supported those players around me,” she said. “I think it’s just been a really special team to be a part of. And I’m very proud of what we have been able to accomplish over the years.” ___ AP soccer: https://apnews.com/hub/soccer Advertisement Advertisement'Unprecedented' Climate Extremes Are Everywhere. Our Baselines For What's Normal Will Need To Change #'Unprecedented' #Climate #Extremes #Everywhere. #Baselines #What's #Normal #Need #Change #USA #Russia #Biden #Ukraine #War #Palestine #Gaza #Israel #Fred Harris, a former U.S. senator from Oklahoma who later moved to New Mexico, has died. Born in 1930, Harris was a Democrat who was elected in 1964 to finish the term of Sen. Robert Kerr, who died. He was elected to a full term in 1966 and served through 1972, when he didn't run for reelection. Other career highlights include chairing the Democratic National Committee in 1969 and 1970 and running for president unsuccessfully in 1976. He later moved to New Mexico, where he became a political science professor at the University of New Mexico. "A passionate champion of Native American rights, Sen. Harris sponsored legislation signed into law by President Richard Nixon that restored land to Taos Pueblo seized by President Theodore Roosevelt and designated as the Carson National Forest early in the 20th century," Gov. Michelle Lujan Grisham said in a statement Saturday. "Later, though his work in academia, Sen. Harris shaped the lives of countless University of New Mexico students who learned firsthand from a political legend about the importance of democracy, good governance, and civil political discourse," she continued. "The Fred Harris Congressional Internship program provided UNM students with opportunities to work on Capitol Hill and learn about the inner workings of Congress and the federal government." New Mexico Sen. Ben Ray Luján said Harris' "life and career in public service was dedicated to lifting others up and working toward the greater good. He fought tirelessly for civil rights, working families, and Native communities. “I am sending my love and prayers to Marg, Senator Harris’ children, and to all who had the privilege of knowing one of the last great statesmen," Luján said. In a statement Saturday, U.S. Rep. Melanie Stansbury hailed his advocacy for Native Americans and civil rights and his support for passing President Lyndon Johnson's Great Society programs. "As a dear friend, colleague, and hero, he will be deeply missed and leave a hole in our community that can never be replaced," she said. "His legacy will live on in all of the young people that he inspired and mentored on their way to becoming leaders in the ongoing fight for justice." This is a developing story and will be updated.
The Conservative government left the courts in financial limbo until June because it failed to settle their funding, the most senior judge in England and Wales has told MPs. Baroness Sue Carr, the lady chief justice, told Parliament's Justice Committee the criminal courts were in a "drastic" state and the previous government had repeatedly failed to offer funds in time for each new financial year. She said the new Labour government’s decision to financially peg back how much work judges could do meant some courts would be out of use, despite record backlogs. She predicted that those cuts would save no money and were "distressing" for victims and everyone else involved in the system. Baroness Carr’s comments on the state of the courts come as the system struggles with record backlogs of around 68,000 open cases in the Crown Courts. Those backlogs have been caused by a combination of complex factors, including the pandemic, but have their roots in a decision to cap justice spending before then. Speaking to MPs on the cross-party committee, Baroness Carr said the outgoing Conservative government had repeatedly failed to offer funding in time and had not made an offer for the 2024-25 financial year, which began in April, until June. "The offer wasn't made until June, and agreement was not reached until June," she said. "The latest it has been agreed, I think, is possibly July, even August. "In the last six years, so far as I'm aware, the concordat agreement has never been reached before the year itself starts." Baroness Carr said that while there were enough judges available to sit on cases for 113,000 days a year, the new government had pegged funding for them 6,500 days below that ceiling. "The decision to limit us to 106,500 has, frankly, had a drastic effect across the board," she said. "Judges have had to take fixed cases out of their lists. They've all had to cancel bookings [of part-time judges]." Baroness Carr said the cases being removed from the schedule includes serious violence and sexual offences - and some of these could not be heard before 2027. "The cases that are being taken out of the lists are cases that were ready to be heard before next April, so cases with judges, staff, courts, advocates, witnesses and complainants available," she said. "Their removals are accompanied by long delays, sometimes years. This has been a most distressing time for witnesses, for police, CPS, advocates, court staff and judges alike." Giving three examples of cuts from south-west England, she told the MPs that Bristol Crown Court had removed "hundreds" of cases from its schedule because it was having to close 40% of its courtrooms a week due to a lack of funds. In Taunton, there would only be 60 court days available between January and March 2025 to run trials that needed 265 days. Truro’s crown court would be shutting one day a week. "This is not about saving anything," she said. "It is not about saving money. You are deferring the cost - and indeed you are increasing it. "You are increasing it because inflation will mean everything costs more. "You are increasing it because barristers and the Crown Prosecution Service are going to have to redo the work they had done to be ready for trial, because the case will be stale. "And that is not even to touch upon the acute social cost... particularly where [sexual offences] complainants simply don't feel able to have confidence in the system anymore and walk away."
No. 2 UConn falls again in Maui, losing 73-72 to Colorado on Jakimovski's off-balance layup
Trump’s tariffs in his first term did little to alter the economy, but this time could be different
Mongolia’s Parliament Chair on 100 Years of Constitutional Democracy
Ian Schieffelin came within two assists of a triple-double and Clemson handed Penn State its first loss with a 75-67 decision for the championship of the Sunshine Slam tournament Tuesday in Daytona Beach, Fla. Schieffelin finished with 18 points, 13 rebounds and eight assists for the Tigers (6-1), leading four players in double figures. Chase Hunter added 17 points, while Chauncey Wiggins scored 14 and reserve Del Jones chipped in 10 points. Clemson sank 9 of 19 3-pointers, converted 16 of 20 free throws and was able to limit the impact of the Nittany Lions' full-court pressure. The Tigers committed just 13 turnovers, helping them hold Penn State (6-1) to less than 85 points for the first time this year. Ace Baldwin starred in defeat with game highs of 20 points and 11 assists, while center Yanic Konan Niederhauser added 14 points. Nick Kern came off the bench to score 11 but Penn State was outscored 15-2 on the fast break and made just 4 of 18 attempts from 3-point range. Schieffelin came up big down the stretch, assisting on a 3-pointer by Jaeden Zackery with 6:04 left that made it 65-61. Then he made two foul shots and tossed in a jump hook from the lane to up the margin to 71-66 with 1:03 left. The big storyline going into this game was which team would be able to control the pace. Penn State came in averaging 96 ppg, while Clemson demonstrated its ability to enforce a slower tempo in March, advancing to a regional final in the NCAA Tournament. In the first 10 minutes of the game, the Tigers made the Nittany Lions play at a crawl, opening up a 17-10 advantage when Schieffelin converted a short hook in the lane. But Penn State answered with an 18-4 run over nearly six minutes, establishing a 28-21 lead when Kern shook free for a layup. Clemson rallied with nine straight points but the Nittany Lions had the last say as Baldwin converted a layup with 24 seconds left, cutting the Tigers' edge to 38-36 at halftime. --Field Level MediaFranklin BSP Realty Trust, Inc. ( NYSE:FBRT – Get Free Report ) announced a quarterly dividend on Monday, December 16th, NASDAQ Dividends reports. Stockholders of record on Tuesday, December 31st will be paid a dividend of 0.355 per share on Friday, January 10th. This represents a $1.42 annualized dividend and a dividend yield of 11.20%. The ex-dividend date is Tuesday, December 31st. Franklin BSP Realty Trust has a dividend payout ratio of 92.8% indicating that its dividend is currently covered by earnings, but may not be in the future if the company’s earnings decline. Equities analysts expect Franklin BSP Realty Trust to earn $1.52 per share next year, which means the company should continue to be able to cover its $1.42 annual dividend with an expected future payout ratio of 93.4%. Franklin BSP Realty Trust Trading Down 0.5 % Shares of Franklin BSP Realty Trust stock opened at $12.68 on Friday. Franklin BSP Realty Trust has a 12-month low of $11.99 and a 12-month high of $14.11. The stock has a market capitalization of $1.04 billion, a P/E ratio of 15.46 and a beta of 1.40. The company has a 50-day simple moving average of $12.97 and a 200 day simple moving average of $13.01. The company has a quick ratio of 90.45, a current ratio of 90.45 and a debt-to-equity ratio of 3.67. Analyst Ratings Changes Read Our Latest Stock Analysis on FBRT Franklin BSP Realty Trust Company Profile ( Get Free Report ) Benefit Street Partners operates as a self-managed real estate investment trust (REIT). BSP earns income from investing in a leveraged portfolio of residential mortgage pass-through securities consisting almost exclusively of adjustable-rate mortgage (ARM) securities issued and guaranteed by government-sponsored enterprises, either Federal National Mortgage Association (Fannie Mae) or Federal Home Loan Mortgage Corporation (Freddie Mac) (together, the government-sponsored enterprises (GSEs)), or by an agency of the federal government, Government National Mortgage Association (Ginnie Mae). Recommended Stories Receive News & Ratings for Franklin BSP Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Franklin BSP Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter .
Voice cloning is an emerging technology powered by artificial intelligence and it's raising alarms about its potential misuse. Earlier this year, New Hampshire voters experienced this firsthand when a deepfake mimicking President Joe Biden’s voice urged them to skip the polls ahead of the primary. The deepfake likely needed only several seconds of the president's voice to create the clone. According to multiple AI voice cloning models, about 10 seconds of an actual voice is all that is needed to recreate it. And that can easily come from a phone call or a video from social media. "A person's voice is really probably not that information-dense. It's not as unique as you may think," James Betker, a technical staff member at OpenAI, told Scripps News. Betker developed TortoiseTTS, an open-source voice cloning model. "It's actually very easy to model, very easy to learn, the distribution of all human voices from a fairly small amount of data," Betker added. How AI voice cloning works AI models have been trained on vast amounts of data, learning to recognize human speech. Programs analyze the data and train repeatedly, learning characteristics such as rhythm, stress, pitch and tone. "It can look at 10 seconds of someone speaking and it has stored enough information about how humans speak with that kind of prosody and pitch. Enough information about how people speak with their processing pitch and its weights that it can just continue on," Betker said. Imagine a trained AI model as a teacher, and the person cloning the voice to be a student. When a student asks to create a cloned voice, it starts off as white noise. The teacher scores how close the student is to sounding correct. The student tries again and again based on these scores until the student produces something close to what the teacher wants. While this explanation is extremely simplified, the concept of generating a cloned voice is based on bit-by-bit, based on probability distributions. "I think, at its core, it's pretty simple," Betker said. "I think the analogy of just continuing with what you're given will take you pretty far here." There are currently some AI models that claim to only need two seconds of samples. While the results are not convincing yet, Betker says future models will need even fewer voice samples to create a convincing clone.Ian Schieffelin, Clemson topple Penn State to win Sunshine Slam